title: Diabetes Outcomes: Comparison of Patient Assistance Programs to 340B Drug Pricing.
abstract: Patient assistance programs (PAPs) or obtaining 340B drug pricing offers a means of providing medications at low cost. The purpose of this study was to determine whether primary care patients who receive insulin from PAPs have an improved change in A1C, compared to 340B patients.
  
  
  
  This was a retrospective study of primary care patients who obtained insulin therapy through a PAP or 340B between June 1, 2012, and June 1, 2013.
  
  
  
  The baseline and change in A1C for PAP patients was similar to 340B patients (10.3% vs. 9.3%) (-0.52 ±2.67 vs. -0.3 ±2.32, p=.66). Baseline and changes in SCr (1.0 vs. 0.99) (0.08 ±0.26 vs. 0.08 ±0.40, p=.93) and BMI (34.0 vs. 33.9) (0.15 ±2.29 vs. 0.10 ±2.16, p=.89) were also similar. PDC values averaged 0.74 in PAP patients, and 0.72 in 340B patients (p=.93).
  
  
  
  This study may serve as a platform for future research.
authors.forename: Laura
authors.initials: L
authors.lastname: Challen
authors.forename: Christine
authors.initials: C
authors.lastname: Kelso
authors.forename: Heather M
authors.initials: HM
authors.lastname: Pautler
authors.forename: Grace
authors.initials: G
authors.lastname: Benanti
mesh_terms: D003363:Cost Control; D003920:Diabetes Mellitus / Q000188:drug therapy*; D016527:Drug Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000627:therapeutic use; D007328:Insulin / Q000191:economics / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin